Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events
Active, not recruitingOBSERVATIONAL
Enrollment
13,000
Participants
Timeline
Start Date
January 1, 2011
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2025
Conditions
Atherosclerotic Vascular DiseaseCoronary Arterial Disease (CAD)Atherosclerosis of Coronary ArteryAtherosclerosis of Arteries of the Extremities, UnspecifiedHeart DiseasesStrokeVenous Thromboembolic Disease
Trial Locations (2)
32209
UF Health, Jacksonville
32608
UF Health, Gainesville
All Listed Sponsors
lead
University of Florida
OTHER
NCT06855394 - Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events | Biotech Hunter | Biotech Hunter